SARS-CoV2 Infection Clinical Trial
— FWCSWG-IL-2Official title:
Fort Worth Clinical Sciences Working Group (FWCSWG) for COVID-19: Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
To explore the efficacy of treatment of pulmonary cytokine storm induced by SARS-CoV2 with a monoclonal antibody to IL-2 (Basiliximab) in addition to current standard of care vs current standard of care with the primary efficacy endpoint being the proportion of subjects alive and free of ventilator support, defined as intubation and requiring mechanical ventilation, at Day 28 from time of randomization.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | December 1, 2022 |
Est. primary completion date | October 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Subject Inclusion Criteria 1. Patient or legally authorized representative (LAR) willing and able to provide written or electronic or otherwise FDA-acceptable informed consent based on current FDA regulations. 2. Hospitalized male or non-pregnant female 3. RT-PCR confirmed SARS-CoV-2 using WHO consensus or validated primers 4. Meet the Following Criteria: 1. Deficiency in Oxygenation as defined by the Berlin ARDS Criteria (27): Timing: Within 1 week of onset of symptoms Imaging: Bilateral pulmonary infiltrates Oxygenation (any): Mild: 200 mmHg < PaO2/FiO2 = 300 mmHg Moderate: 100 mmHg < PaO2/FiO2 = 200 mmHg Severe: PaO2/FiO2 = 100 mmHg and 2. Requiring oxygen support in the form of High Flow Nasal Cannula (HFNC), non-invasive positive pressure ventilation, intubation and mechanical ventilation, or initiation of ECMO and 3. Any one or more of the following: 1. Elevated CRP (>10 gm/dL) 2. Elevated Ferritin (>1000) 3. Neutrophil/lymphocyte ratio >3.3 5. Patient will receive current clinical standard of care. This includes inpatient use of remdesivir, dexamethasone, convalescent plasma, or pre-hospitalization outpatient treatment with casirivimab and imdevima 6. Age = 18 years Exclusion Criteria: 1. Off label use of other drugs 2. WOCBP unwilling to use acceptable birth control for 5 weeks, or male partner of a WOCBP unwilling to use male barrier method (condom) plus effective second method birth control for partner 3. Pregnant women 4. Pancytopenia 1. Hgb< 8 g/dL (male) or < 7 g/dL (female) 2. WBC<2.0 x 109/L 3. PLT< 50 x 109/L 4) Enrollment in any study using immunomodulatory therapies (monoclonal antibodies, small molecule inhibitors etc. to interleukins or interleukin-receptor) 5) Any subjects who have received treatment with immunomodulators or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 agents, and JAK inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. 6) Known/established systemic bacteremia (empiric antibiotics are allowed), uncontrolled viral infection besides the SARS-CoV-2 study disease, significant abscess in the opinion of the investigator, or any other finding that, in the opinion of the investigator, poses undue risk for treatment with basiliximab. 7) Any patient with multi-organ system failure or on intravenous vasopressor support 8) Do-not-resuscitate status at time of consent, or any contraindication to invasive mechanical ventilation |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fort Worth Clinical Sciences Working Group | TCU and UNTHSC School of Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | ICU length of stay | Exploratory | From time of randomization to Day 90 | |
Other | Hospital length of stay | Exploratory | From time of randomization to Day 90 | |
Other | ICU length of stay + death composite endpoint | Exploratory | From time of randomization to Day 90 | |
Other | Hospital length of stay + death composite endpoint | Exploratory | From time of randomization to Day 90 | |
Other | Improvement in 8-point ordinal scale | Improvement in 8-point ordinal scale | From time of randomization to Day 28 | |
Other | Decline in serum albumin | Decline in serum albumin | From time of randomization to Day 28 | |
Other | proportion alive and free of ventilator support stratified by IV dexamethasone | proportion alive and free of ventilator support stratified by IV dexamethasone | From time of randomization to Day 28 | |
Primary | Primary Efficacy Endpoint | 1. Proportion of subjects alive and free of ventilator support, defined as intubation and requiring mechanical ventilation, at Day 28 from time of randomization | From time of randomization to Day 28 | |
Secondary | Avoidance of escalation of O2 therapy | Avoidance of escalation in oxygen therapy from the time of randomization to Day 28, defined as a binary endpoint, in which an increase from the baseline level of oxygen support to any of the following in the sequence listed below is considered an escalation, allowing for assessment of change in oxygen support at levels less than or greater than intubation and mechanical ventilation. Changes in level of oxygen therapy that occur prior to Day 28 are not accounted for in this endpoint.
Non-invasive positive pressure ventilation Intubation and mechanical ventilation Initiation of ECMO, with or without intubation and mechanical ventilation Death |
From time of randomization to Day 28 | |
Secondary | Overall Survival | Overall survival, defined as proportion of subjects alive at Day 28 from time of randomization | From time of randomization to Day 28 | |
Secondary | ICU Free Survival | ICU-free survival, defined as proportion of subjects alive and not requiring ICU hospitalization at Day 28 from time of randomization | From time of randomization to Day 28 | |
Secondary | ECMO Free Survival | ECMO-free survival, defined as proportion of subjects alive and not requiring ECMO support at Day 28 from time of randomization | From time of randomization to Day 28 | |
Secondary | Overall Survival at 90 days | Overall survival, defined by time to event analysis at Day 90 | From time of randomization to Day 90 | |
Secondary | Ventilator-free survival at 90 days | Ventilator-free survival, defined by time to event analysis at Day 90 | From time of randomization to Day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Recruiting |
NCT05311410 -
Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures
|
N/A | |
Active, not recruiting |
NCT05073718 -
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
|
Phase 3 | |
Completed |
NCT05055492 -
The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions
|
N/A | |
Completed |
NCT05060510 -
The School SPIT Study - COVID-19 Testing in Secondary Schools
|
N/A | |
Completed |
NCT05055505 -
The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions
|
N/A | |
Completed |
NCT05054218 -
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
|
||
Completed |
NCT05449392 -
Topical Antibacterial Agents for Prevention of COVID-19
|
Phase 1 | |
Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05172024 -
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
Withdrawn |
NCT05067946 -
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT05116657 -
Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
|
||
Recruiting |
NCT04590222 -
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
|
||
Completed |
NCT04551911 -
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
|
Phase 2 | |
Completed |
NCT04953039 -
Use of Saliva for COVID-19 Diagnosis
|
||
Active, not recruiting |
NCT06181292 -
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
|
Phase 2/Phase 3 |